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Abstract  
Background: Excessive sun exposure and high human immunodeficiency virus prevalence increase skin 
cancer risk in South Africa.  
Objective: To describe the nature and extent of skin cancers presenting in public and private health 
sectors of the Northern Cape Province.  
Methods: A retrospective analysis of histologically-confirmed new primary cutaneous malignancies 
from 1/1/2008 to 31/12/2012 was conducted using public and private health sector databases. Types, 
quantity and distribution of common invasive malignancies by population group, age, gender, 
anatomical site and health sector were explored. One-year cumulative incidence was calculated and 
logistic regression models were used to analyse incidence and melanoma thickness trends. 
Results:  4270 biopsies (14 cutaneous malignancies) were identified. Most common were Squamous 
Cell Carcinoma (SCC), Basal Cell Carcinoma (BCC), Kaposi Sarcoma (KS), Cutaneous Malignant 
Melanoma (CMM) and Basosquamous carcinoma. The odds of a White male developing SCC increased 
by 8% each year (OR: 1.08; CI: 1.01-1.15; p-value: 0.022) whilst the odds of a Black male developing 
SCC and KS decreased by 9% (OR: 0.91; CI: 0.84-0.99; p-value: 0.033) and 18% (OR: 0.82; CI: 0.70-
0.97; p-value: 0.022) each year, respectively. SCC and CMM were diagnosed at more advanced stages 
within public versus private sectors. CMM is being detected earlier, as indicated by low stage depth 
increasing by 72% annually (OR: 1.72; 95% CI: 1.04-3.01; p-value: 0.042).  
Conclusion: Results suggest that reported skin cancer patterns are changing. There is a need for further 
research and equitable appropriation of financial resources and effort toward developing primary skin 
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  Chapter 1: Introduction and literature review                      
1.1 Introduction 
South Africa (SA) spans the latitude 22° S to 34° S and due to its location within the subtropics, most 
parts of the country have high levels of solar ultraviolet radiation (UVR).[1] This is particularly the case 
with the Northern Cape (NC) Province, which is the country’s largest and most arid province, the 
vegetation consisting mainly of scrubland, with trees often limited to watercourses.[2] Despite its 
geographic size, the NC Province has the smallest population, with only 1.18 million individuals 
inhabiting it.[3] Its economy relies mainly on mining and agriculture, and 18.5% of the currently 
employed NC population work within the agricultural industry.[4] A total of 90% of Non melanoma skin 
cancer (NMSC) is attributed to personal exposure to UVR and thus South Africans are especially 
susceptible to skin cancer due to their year-round exposure to high ambient solar UVR.[5] Individuals 
working outdoors are at an even greater risk, as they will probably spend most daylight hours outside 
and thus have a 43% and 77% higher risk of developing basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) respectively.[6,7] The incidence of both NMSC and cutaneous malignant melanoma 
(CMM) is on the increase globally, with reporting systems being essential to monitor the number of 
cases and the trends over time.[8,9] However, due to limited private sector submissions to the South 
African National Cancer Registry (NCR), the last comprehensive data inclusive of all health sectors was 
published in 2004, making it difficult to establish whether skin cancer incidence in SA has followed the 
global trend.[10] This study therefore, aimed to collate and analyse public and private sector data for the 
NC province over a five-year period to provide insight into the local skin cancer burden and potentially 
give an indication of the skin cancer problem in SA at large. The literature review addresses issues 
relating to the pathogenesis of skin cancer, types of skin cancer, their origins and key characteristics, as 
well as risk factors for skin cancer development. It provides a global and local perspective on skin 
cancer incidence and reviews current initiatives to combat skin cancer in SA and the need for up-to-date 
skin cancer statistics. 
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1.2 Literature review 
1.2.1 The pathogenesis of skin cancer  
Carcinogenesis refers to the production of cancer, and it is a multistep process that occurs as a result of 
the accumulation of mutations in vital regulatory pathways which, after various stages of precancerous 
proliferation, result in the transition to the malignant phenotype.[11] Skin cancer is the uncontrolled 
growth of abnormal skin cells, its formation being based on constitutional and/or inherited factors often 
combined with environmental factors such as exposure to ultraviolet or ionizing radiation, various 
chemicals or oncogenic viruses.[12] 
 
Exposure to ultraviolet light results in the formation of deoxyribonucleic acid (DNA) photoproducts and 
the generation of reactive oxygen species that cause DNA damage. UV-light damaged DNA is either 
repaired or if this cannot be done, the DNA damaged cells are removed by apoptosis. With excessive 
chronic exposure to UVR, repair pathways are overwhelmed, allowing photoproducts to persist, which 
interfere with DNA replication and result in mutations.[12] The starting point for the development of SCC 
is formation of mutations within the p53 tumour suppressor gene. The molecular basis for BCCs 
originate through UV light mediated mutations of the PTCH1 gene of the Hedgehog signalling pathway, 
this being vital to maintain cell growth and differentiation. Mutations in genes controlling cell 
proliferation and apoptosis result in clonal expansion, which results in various stages of precancerous 
proliferation ensuing and leads to the development of additional mutations, and ultimately transition to a 
malignant neoplasm.[12] 
 
Oncogenic viruses can transform keratinocytes by activating cancer-promoting genes. The viral proteins 
may act directly as oncogenes that stimulate cells to multiply or they may initiate inflammatory 
responses and cause the regeneration of damaged cells that ultimately may lead to malignant 
transformation.[13] Ionising radiation can cause DNA damage directly itself or indirectly through free 
radical formation.[14] Chemical carcinogens may act as initiators, which directly cause mutations in 
DNA, or act as promoters that lead to proliferation of initiated cells.[15]  
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1.2.2 Types of skin cancer, their origins and key characteristics 
Skin cancer is broadly divided into non-melanoma and melanoma skin cancers, the former referring to 
all other malignant tumours that arise in the cells of the skin other than melanocytes.[12] Melanocytes are 
melanin-forming cells located in the basal layer of the epidermis of the skin.[12] Melanoma skin cancer 
includes all types of CMMs, which are aggressive malignant tumors arising from  
melanocytes.[12] 
 
1.2.2.1 Non-melanoma skin cancer 
Eight broad groups of NMSC will be reviewed. 
a. Basal cell carcinoma  
BCC originates in the basal cell layer of the epidermis and is responsible for about 75% of NMSCs.[16] It 
typically develops on chronically sun-exposed areas of the skin, especially the head and neck.[16] It is 
slow growing and very rarely metastasizes, although if left untreated, it may spread to adjacent tissues 
and even bone. There are a number of BCC subtypes with different morphological characteristics 
namely nodular, superficial, morpheaform and fibroepithelial.[16] 
b. Squamous cell carcinoma  
SCC accounts for about 20% of NMSCs and originates from the more superficial layers of the epidermis 
with a tendency to be more aggressive than BCC.[17] It can invade adjacent tissues as well as spread to 
lymph nodes and distant sites. It usually appears on sun-exposed areas such as the face and backs of the 
hands, but also has a tendency to develop within areas of chronic inflammation including scars and 
chronic ulcers. When an SCC develops within a chronic wound it is known as a Marjolin’s ulcer.[17] The 
incidence of SCC usually increases significantly after age 60, Precursors to SCC include actinic 
keratosis and SCC in situ, which is also known as Bowen’s disease.[17] 
c. Basosquamous carcinoma (BSC) 
BSC, also known as a metatypical BCC, is a tumor that has histologic features of both a BCC and a 
SCC. These malignancies tend to behave more like SCC’s in that they are more aggressive and have a 
greater likelihood of both metastasizing and recurring after treatment.[17] 
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d. Malignant vascular tumours 
Malignant vascular tumours are vascular neoplasms arising from endothelial cells, with the majority 
being sarcomas.[18] Kaposi sarcoma (KS) and angiosarcoma fall within this group. 
KS is a low-grade vascular tumour associated with infection with human herpes virus 8 (HHV-8) and 
can develop both within the dermis and internal organs.[19] There are four major types of KS namely 
Classic, African endemic, Iatrogenic immunosuppression and acquired immune deficiency syndrome 
(AIDS)-related. The latter is by far the most commonly seen in SA and is considered an AIDS-defining 
illness,[20] with a variable clinical course, ranging from minimal disease to a rapidly progressing 
malignancy that can result in significant morbidity and mortality.[19] Angiosarcoma is an aggressive 
neoplasm that tends to develop on the face or scalp of elderly individuals. It has a poor prognosis with 
less than 15% of patients surviving five years.[21] Risk factors for its development will be expanded upon 
in section 1.2.3. 
e. Primary cutaneous lymphomas  
Primary cutaneous lymphomas can be divided into primary cutaneous T-cell lymphomas (CTCL) and 
primary cutaneous B-cell lymphomas, comprising 75% and 25% respectively. CTCL’s are a group of 
neoplasms of skin-homing T-cells.[22] Mycosis Fungoides is the most common type of CTCL and 
comprises about half of all primary cutaneous lymphomas. It is a low-grade lymphoma characterized by 
a protracted course clinical course, typically progressing from the patch stage to plaque to tumour  
stage.[22] 
f. Malignant adnexal neoplasms 
This group of malignant tumours exhibits differentiation towards a type of cutaneous adnexal 
epithelium, namely the pilosebaceous unit, eccrine or apocrine sweat glands. It includes the sebaceous 
carcinoma, pilomatrical carcinoma, porocarcinoma, spiradenocarcinoma, cyclindrocarcinoma and 
adnexal adenocarcinoma.[23] 
g. Malignant fibroblastic tumours  
These neoplasms represent a very large subset of mesenchymal tumours.[24] 
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Dermatofibrosarcoma protuberans is a locally aggressive sarcoma of intermediate malignancy that 
rarely metastasizes. It occurs predominantly on the trunk and proximal extremities and presents as a 
slow growing, firm, indurated, asymptomatic plaque.[24] 
h. Malignant cutaneous neural tumours 
Cutaneous neural tumors can be classified into two major groups, derived from either peripheral nerves 
or ectopic neural tissue.[25] Merkel cell tumour is an aggressive malignant neoplasm falling within the 
former group and frequently metastasizes to internal organs.[25] 
 
 1.2.2.2 Melanoma skin cancer 
a. Cutaneous malignant melanoma  
Although CMM occurs less frequently than some of the other major cutaneous neoplasms, it is 
significantly more dangerous if not found in the early stages and due to its metastatic potential is 
responsible for  > 75% of deaths due to skin cancer.[26] Major subtypes of invasive CMM include 
superficial spreading, lentigo maligna, acral lentiginous and nodular melanoma.[26] Risk factors for 
CMM development are elaborated on in section 1.2.3.  
 
1.2.3 Risk factors for skin cancer development 
Risk factors for the development of NMSC and CMM can be divided into environmental exposures, 
preexisting pathology and genetic risk factors. 
 
1.2.3.1 Environmental exposures 
Exposure to certain environmental factors plays a major role in predisposing to skin cancer 
development. 
 a. Ultraviolet radiation  
 UVR exposure is the predominant cause of BCCs and cutaneous SCCs with intermittent intense 
exposure being the major risk factor for developing BCCs and cumulative exposure for SCC.[16,17] A 
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systematic review of case control studies has found a strong association between CMM, intermittent 
intense exposure and sunburn in childhood and adolescence.[27]  
b. Tanning lamps, ionizing radiation and photochemotherapy  
Tanning lamp usage and exposure to ionizing radiation increase the risk of developing NMSC.[16,17] 
Long-term exposure to UVA combined with the intake or application of psolaren (PUVA), increases the 
risk of SCC development.[17] Chronic radiodermatitis is a risk factor for angiosarcoma.[21] 
c. Chemical exposures 
Exposure to arsenic, pesticides and polycyclic aromatic hydrocarbons increase the risk of the developing 
SCC.[15] 
 
1.2.3.2 Preexisting pathology 
A variety of pathological conditions are risk factors for skin cancer development. 
a. Immunosuppression  
Organ transplant recipients have a markedly increased incidence of NMSC, primarily SCC, with  
immunosuppressive drugs including calcineurin inhibitors and azathioprine increasing the risk of their 
development.[28] Immunosuppression is also a risk factor for developing angiosarcoma.[21] 
b. Viral Infections  
Human immunodeficiency virus (HIV) infection increases the risk of developing NMSC by 3-5     
fold.[29] Both CMM and SCC have a more aggressive course in patients with HIV.[30] 
HHV-8 causes KS, which is 50 times more likely to develop in individuals infected with HIV.[29] 
Fortunately, the introduction of antiretroviral therapy (ART) has helped to decrease the incidence, 
mortality and morbidity associated with HIV-associated KS in SA.[31] 
Human papilloma virus (HPV) subtypes, namely HPV 16, 5, and 8 act as co-carcinogens in 
conjunction with UVR exposure in the early development of SCC.[28] 
Merkel cell polyomavirus is the cause of most Merkel cell carcinomas.[25] 
c. Chronic inflammation                                                                                                                          
There is an increased risk of cutaneous SCC developing in chronically inflamed skin as a result of burns, 
scars and chronic ulcers.[17]  
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d. Lymphoedema                                                                                                                                    
Chronic or congenital lymphoedema is a risk factor for the development of angiosarcoma.[21] 
e. Nevi                                                                                                                                           
Individuals with >5 atypical nevi or  >100 typical nevi are at higher risk for developing CMM.[32] 
 
1.2.3.3 Genetic risk factors 
Hereditary factors and gene mutations may predispose to the development of skin cancer. 
a. Genetic predisposition                                                                                                                
Phenotypic characteristics such as red or blonde hair, light skin pigmentation, freckling, little ability to 
tan and light eye colour are risk factors for NMSC and CMM,[17, 26] whilst 10% of melanomas are 
familial.[33] Angiosarcoma of the face or neck occurs significantly more commonly in elderly White 
population groups.[21] 
b. Genetic syndromes associated with increased risk                                                                    
Xeroderma pigmentosum and oculocutaneous albinism (OCA) heighten the risk of developing NMSC. 
Patients with epidermodysplasia verruciformis and dystrophic epidermolysis bullosa are also at risk of 
developing SCC, while those with Nevoid basal cell carcinoma syndrome and Bazex syndrome are at 
high risk of developing BCC.[16, 17] 
 
1.2.4 A global perspective on skin cancer incidence 
Annual skin cancer incidence is determined by the number of histologically confirmed new primary 
cutaneous malignancies occurring over a one-year period of time.[34] Over a number of years trends in 
incidence can be calculated. A recent systematic review of the worldwide incidence of NMSC, has 
found an increase in its incidence globally.[8] NMSC incidence varies widely, with the highest rates in 
Australia and the lowest in parts of Africa. The incidence of BCC in Europe is increasing at a rate of 5% 
per year, while in the United States of America an annual increase of 2% is apparent.[8] Due to 
intermittent UVR exposure being more critical than total UVR exposure in the aetiology of BCC, those 
exposed to long-term UVR, as is the case in some subgroups of the Australian population, have an 
increased likelihood of developing SCC than those in regions like the United Kingdom (UK), where 
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intermittent exposure is more frequent. This is reflected by the BCC: SCC ratio, which in Australia is 
approximately 5: 2 and in the U.K. is 4: 1.[8]
 
 
The incidence of CMM is increasing at 3-7% per year in fair-skinned populations globally,[9]while in 
Black and Asian populations it remains low in comparison.[35] However, in Black patients, the five-year 
relative survival rate is lower than in the White population, which may be due to delayed diagnosis  
related to a perceived lower risk and to atypical locations of CMM in nonexposed areas.[36] The 
dermoscopic features of a melanoma do not differ between dark and light-skinned individuals, thus 
identification of a suspicious lesion in a person of colour, should not pose an obstacle to the trained      
eye.[37] Clark level and Breslow depth describe the anatomical involvement and depth of invasion of a 
CMM respectively.[38] (Appendix 1& 2) Tumour thickness is an indicator of the effectiveness of early 
detection of melanomas. In many countries there is an on going trend toward early detection and 
therefore thinner melanomas being detected, while the percentage of melanoma seen insitu has 
increased.[39] 
 
1.2.5 Skin cancer in Sub-Saharan Africa  
In Sub-Saharan Africa (SSA), the highest incidence rates of NMSC have been found in Zimbabwe and 
SA, which have a higher proportion of light skinned individuals than the other African countries.[34] The 
frequency of cutaneous malignancies among darkly pigmented individuals of the developing world is 
much lower,[40] but the true occurrence is yet to be fully characterized, as under-reporting especially 
from SSA, is highly likely.[29] The reports that have been compiled thus far indicate that both SCC and 
KS rank among the top ten most frequent malignancies in these populations, and that SCC is the most 
common skin cancer in Black Africans and African Americans.[29] Chronic ulcers and scars are the major 
risk factors for SCC in black individuals.[41] SCC due to a chronic ulcer has a 30% metastasis rate in 
comparison to the 2-4% metastasis rate in SCC associated with exposure to solar UVR.[37] This may 
explain the poorer outcomes observed in black patients with SCC.[42] 
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In contrast to White populations where 90% of CMM’s develop on sun-exposed skin, 60% of CMM in 
Black Africans are found on unexposed sites, with acral lentiginous melanoma (ALM) being the most 
common histological subtype.[43] Trauma has been speculated as a possible aetiological factor in the 
plantar predilection of CMM in Black African individuals but additional research is required in this 
regard.[44] Socioeconomic factors influence disease outcomes of CMM and less affluent groups tend to 
be diagnosed with more advanced disease and hence poorer survival rates.[44] 
 
 Individuals with OCA have impaired formation of the UV-protective pigment called melanin. OCA is a 
known risk factor for developing skin cancer, with SCC developing most frequently while CMM is       
rare.[45] The risk of an African individual with OCA developing SCC in contrast to the general public has 
been reported to be as high as up to 1000 fold.[46] A high rate of OCA is found in some African ethnic 
groups such as the Tonga tribe in Zimbabwe which has a frequency of 1/ 1000.[47] 
 
1.2.6 Skin cancer in South Africa 
South Africans are particularly susceptible to skin cancer due to their exposure to year-round high 
ambient solar UVR.[5] In a population of 54 million, the ethnic mix within SA shows a diverse 
population, consisting of Black (80.2%), White (8.4%), Coloured (8.8%) and Asian/Indian (2.5%) 
population groups.[48] The incidence of NMSC in White South Africans, was found to be four fold higher 
than rates in the UK and France.[49] The outcome of a survey of all histologically confirmed cases of skin 
cancer (n=44,716) that were reported to the National Cancer Registry (NCR) between 2000 and 2004 are 
illustrated in Table 1.[50] 
 
Table 1. Mean annual age-standardised incidence of reported BCC, SCC and CMM per 100,000 
persons in SA, 2000-2004[50] 
 
Type of carcinoma Black Asian/Indian Coloured White 
BCC 4.7 13 85.7 311.1 
SCC 4.6 7 41.5 101.3 
CMM 2.2 1.8 10 37 
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The White population had the highest reported incidence of all three skin cancers, followed by the 
Coloured, then Indian/Asian and Black populations. Although in comparison, age standardised incidence 
rates were low in Indian/Asian and Black population groups, they were still higher than those found in 
other African countries.[34] The reason for this is thought to be due to their fairer skin, in relation to the 
darker skin of individuals found in the rest of the continent.[34] As Black individuals comprise 80% of the 
SA population, even the low rates of SCC, BCC and CMM in this group, may be consequential in terms 
of the national health burden.  
 
HIV infection increases the risk of NMSC and SA has one of the world’s largest HIV epidemics, with 
11,2% of the population (6.19 million individuals) being HIV positive.[3, 29] Thus it can be inferred that 
HIV has played a role in increasing NMSC incidence in the country. Fortunately 42% of HIV infected 
South Africans have been initiated on ART and a recent meta-analysis has shown that these individuals 
have a lower risk of developing NMSC than those not initiated on treatment (standardised incidence 
ratio, 95% confidence interval; 1.95 [1.10-3.47] versus 2.11 [1.44-3.12]). [51, 52] 
 
Although completely accurate South African skin cancer data is not available after 2004 (see section 
1.28 below), the estimated yearly incidence of CMM in 2014 was 4.76 per 100,000 persons overall and 
19.2 per 100,000 in whites.[53] A comparative study conducted in SA concurred with previous 
observations in the literature and found a poorer prognosis for CMM in dark skinned individuals, with a 
20% and 42% five-year survival rate in blacks and whites respectively.[54] The cause for this has been 
attributed to the late presentation commonly observed in the Black population, in whom the most 
common subtype is ALM. This subtype has a poorer prognosis due to depth of invasion at diagnosis, 
with a five-year survival rate of less than 50%.[29]  
 
1.2.7 Current initiatives to combat skin cancer in South Africa 
Two recent and promising South African skin cancer prevention initiatives are the Skin Cancer 
Foundation of South Africa (SCFSA) and the Nivea Sun Smart programme. The SCFSA was launched 
at the end of 2013 and is an independent, self-funded organisation, dedicated to preventing skin cancer 
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by increasing public awareness.[55] It has implemented a national skin cancer screening day on the 1st of 
September each year, on which South Africans can be screened free of charge for skin cancer by a 
Dermatologist. The Nivea Sun Smart programme has been operating in the KwaZulu-Natal province 
since 2014, and provides age-appropriate education on sun protection at junior and high schools.[56] It 
also offers a service installing sunscreen dispenser units at schools and refilling them monthly. In 
addition, SA has the largest antiretroviral treatment programme globally which is also helping to 
decrease the risk of skin cancer development in HIV positive persons.[51] 
 
1.2.8 The need for up-to-date skin cancer statistics 
Within White populations, NMSC has the highest incidence of all cancers,[8] in spite of this it is seldom 
included in national cancer statistics around the world, with very few publications reviewing incidence 
rates in each country. Although NMSC does have a low mortality rate, it may impact affected persons’ 
quality of life, and is putting a large financial burden on health care services. In the UK, updates to the 
National Institute for Clinical Excellence (NICE) guidelines have highlighted the need to assess the true 
epidemiology of NMSC and to bring skin cancer registration in line with other malignancies, to enable 
accurate prevention studies to be conducted on the effects of sun protection.[57] The findings drawn from 
the data on skin cancer incidence are beneficial for a number of reasons including: 
 
a. Detection of changes in cancer patterns                                                                                                 
Changes in the cancer patterns previously observed in SA can be expected. This is because the incidence 
of NMSC is increasing globally and SA has a large population of HIV infected individuals, which 
increases the risk of NMSC and KS.[29, 58] 
 
b. Enabling the monitoring of skin cancer cumulative incidence (CI) at provincial and national levels                
The incidence of CMM and NMSC in the South African White population already ranks among the 
highest in the world.[8, 59]  Despite occurring much less frequently, both BCC and SCC are ranked among 
the top ten malignancies in Black African males.[34] Increased life expectancy due to improved standards 
of living, progressive ozone depletion and westernisation of social and behavioural attitudes are all 
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expected to increase the burden of skin cancer in SA in the 21st century.[59] Taking into consideration the 
high incidence that currently prevails and the predications that this incidence is likely to rise further, it 
seems prudent to monitor incidence levels provincially and nationally. 
 
c. Provision of a framework to measure the effectiveness of currently implemented skin cancer  
    prevention programmes 
    Accurate up-to-date statistics for a few years continuously, make it possible to identify trends in 
    incidence. A decreasing trend in skin cancer incidence may provide proof that skin cancer prevention 
    programmess are being effective. 
 
d. Encourage increased government allocation of financial resources towards developing sustainable 
    skin cancer prevention policies and strategies 
    In Australia, primary prevention strategies, such as the SunSmart programme that was implemented in 
    the early 1980’s, only began having effects on reducing incidence twenty years later, due to risk of 
    developing NMSC being related to a number of lifelong factors.[8] This should encourage the 
    government to act timeously and allocate adequate finances towards the development of skin cancer 
    prevention strategies. 
 
 e. Help to ensure the adequate allocation of financial resources to diagnose and treat skin cancer  
     A cost-of-illness study was performed in 2015 to measure the economic burden of skin cancer in 
     SA. The estimated total annual cost of treating skin cancers in SA was ZAR92.4 million.[60] 
     Provision will need to be made for this sizeable cost to the already strained healthcare budget.  
 
  f. Promotion of increased awareness among medical practitioners 
     Skin cancer incidence studies may help to make medical practitioners more aware of how common 
     certain cutaneous malignancies are, as well as what age and population groups are at increased risk 
     and thus warrant careful, frequent examination. It may also help to increase cognisance that dark- 
     skinned individuals are also susceptible to developing skin cancer. This is important as pigmented 
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     lesions are difficult to examine in dark skin and may initially be missed,  which could result in late 
      commencement of treatment. Additionally, published data on skin cancer incidence may help to raise 
      awareness that HIV increases the risk of developing NMSC and thus suspicious lesions in these 
      patients must not be overlooked.  
 
Cancer statistics in SSA are generally scanty and therefore unreliable due to a lack of functional 
population based cancer surveillance systems and national registries.[61] The development and progress 
of the South African NCR was hampered from 2005-2010 by a lack of funding, shortages of relevant 
manpower and decreased private sector submissions following concerns regarding patient 
confidentiality. These limitations resulted in the NCR being unable to capture, code, and analyse the 
available or required data and led to a ten-year backlog of incidence reports.[10] In 2011, the South 
African Department of Health created Regulation No 380 of the National Health Act (Act 61 of 2003), 
which made cancer a reportable disease.[62] This differs from a notifiable condition, which relates to 
disease outbreaks where timing is critical to public health and therefore the healthcare provider has a 
limited time in which to report the case.[63] The new act will require all histologically confirmed cases of 
cancer to be reported to the NCR within three months.[62] In addition to this landmark event, the 
repositioning of a cancer surveillance system as a national health priority, supported by stable NCR 
leadership and extended collaborations have enabled the NCR to become fully operational,[10] resulting 
in the 2010 cancer report having been recently published, albeit without all private sector   data.[64] The 
NCR has expressed the view that cancer incidence in SA is under-reported due to the lack of a 
comprehensive cancer surveillance system. Thus over the next ten years it is committed to developing a 
network of independent population-based cancer registries based in a variety of clearly defined districts. 
The heterogeneous catchment populations will be representative of the ethnic and geographical diversity 
of the South African population. Each registry will report annually to the NCR to provide a reliable and 
comprehensive indication of cancer incidence for the entire country.[10] Their aim is to publish cancer 
incidence data for SA, within a worldwide-accepted lag period of 3–5 years.[65] These plans are 
opportune, as concern has been expressed that if incidence rates continue to rise unchecked, skin cancer 
may begin to represent a major health problem and a significant burden to the South African private and 
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public health sectors.  
 
1.2.9 Aim and objectives 
The study aimed to describe the nature and extent of different types of histologically confirmed skin 
cancers presenting in the public and private health sectors of the NC province from 1st January 2008 to 
31st of December 2012.  
 
The objectives were to conduct a retrospective chart review of histologically confirmed new primary 
cutaneous malignancies from 1/1/2008 to 31/12/2012 on cases in the DISA, PathCare and Ampath 
databases. The different types of skin cancer, quantity of each and the distribution of the five commonest 
invasive malignancies by population group, age, gender, anatomical site and health sector were 
explored. The CI of the five commonest invasive malignancies and their trends over five-years were 
calculated. Trends in melanoma thickness over five years were explored.  
 
This is the first South African study to collate and analyse public and private skin cancer data for an 
entire province. The study provides insight into the skin cancer burden faced by the NC Province and 
may give an indication of the skin cancer problem in SA at large. It provides a basis to allow for future 
monitoring of skin cancer incidence at a provincial level, and may aid in detecting changes in cancer 
patterns in the future. It may assist in providing a stimulus for the development of appropriate policies 
on cancer prevention, and may help to increase government allocation of financial resources towards 
developing sustainable prevention strategies. It may also provide a framework to measure the 
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Abstract  
Background: Excessive sun exposure and high human immunodeficiency virus prevalence increase skin 
cancer risk in South Africa.  
Objective: To describe the nature and extent of skin cancers presenting in public and private health 
sectors of the Northern Cape Province.  
Methods: A retrospective analysis of histologically-confirmed new primary cutaneous malignancies 
from 1/1/2008 to 31/12/2012 was conducted using public and private health sector databases. Types, 
quantity and distribution of common invasive malignancies by population group, age, gender, 
anatomical site and health sector were explored. One-year cumulative incidence was calculated and 
logistic regression models used to analyse incidence and melanoma thickness trends. 
Results:  4270 biopsies (14 cutaneous malignancies) were identified. Most common were Squamous 
Cell Carcinoma (SCC), Basal Cell Carcinoma (BCC), Kaposi Sarcoma (KS), Cutaneous Malignant 
Melanoma (CMM) and Basosquamous carcinoma. The odds of a White male developing SCC increased 
by 8% each year (OR: 1.08; CI: 1.01-1.15; p-value: 0.022) whilst the odds of a Black male developing 
SCC and KS decreased by 9% (OR: 0.91; CI: 0.84-0.99; p-value: 0.033) and 18% (OR: 0.82; CI: 0.70-
0.97; p-value: 0.022) each year, respectively. SCC and CMM were diagnosed at more advanced stages 
within public versus private sectors. CMM is being detected earlier, as indicated by low stage depth 
increasing by 72% annually (OR: 1.72; 95% CI: 1.04 -3.01; p-value: 0.042).  
Conclusion: Results suggest that reported skin cancer patterns are changing. There is a need for further 
research and equitable appropriation of financial resources and effort toward developing primary skin 
cancer prevention initiatives in South Africa. 
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Introduction  
 
Due to its location, most parts of South Africa (SA)  have high levels of solar ultraviolet radiation 
(UVR).[1] Despite its geographical size, the Northern Cape (NC) Province has the smallest population, 
with only 1.18 million inhabitants. [2] Its economy relies mainly on mining and agriculture and almost 
one fifth of the currently employed NC population work outdoors within the agricultural industry.[3] 
Approximately 90% of non-melanoma skin cancer (NMSC) is attributable to personal UVR exposure 
and thus South Africans are especially susceptible to skin cancer due to their year-round exposure to 
high ambient solar UVR.[4] Individuals working in outdoor occupations are at an even greater risk of 
NMSC, as they are likely to be outside for more daylight hours.[5, 6] SA has one of the world’s largest 
human immunodeficiency virus (HIV) epidemics,[7] with infected individuals having a 3-5 fold and 50 
fold increased risk of developing NMSC and HIV-associated Kaposi Sarcoma (KS), respectively.[8]  
 
Incidence of NMSC and cutaneous malignant melanoma (CMM) is increasing globally, thus reporting 
systems to monitor number of cases and trends over time are essential.[9, 10] However, due to limited 
private sector submissions to the National Cancer Registry (NCR), the last comprehensive data inclusive 
of all health sectors was published in 2004, making it difficult to establish whether skin cancer incidence 
in SA has followed the global trend.[11]  
 
In 2011, the South African Department of Health passed a regulation,[12] which made cancer a reportable 
disease, requiring all histologically-confirmed cases be reported to NCR.[13] Concerns have been raised 
that if skin cancer incidence continues to rise unchecked, it may become a major health problem and 
place a large financial burden on private and public health services. Of additional concern is that 
melanomas of depth greater than 4mm carry a high risk of mortality. [14, 15]As tumour thickness provides 
an indication of how early a melanoma has been detected, monitoring trends in melanoma thickness to 
assess whether thinner melanomas are being detected may be appropriate.[16] This study aimed to 
describe the nature and extent of different types of histologically-confirmed skin cancers presenting in 
the public and private health sectors of the NC province to provide insight into the local skin cancer 




A retrospective chart review of histologically-confirmed new primary cutaneous malignancies from the 
1st of January 2008 to the 31st of December 2012 was conducted. Different types of skin cancer, quantity 
of each and the distribution of the five commonest invasive malignancies by population group, age, 
gender, anatomical site and health sector were explored. The incidence of the five commonest invasive 
malignancies and their trends over five years were calculated. Trends in melanoma thickness were 
analysed.  
 
Skin biopsies from public facilities within the NC are sent to the National Health Laboratory Service 
(NHLS) histopathology laboratory, while those from private facilities are sent to either PathCare or 
Ampath laboratories. Data on all incident cases was extracted by performing a Systemised 
Nonmenclature of Medicine (SNOMED) search of the DISA, PathCare and Ampath databases, using the 
SNOMED codes for all cutaneous malignancies. The data extracted from the histopathology reports for 
each patient included the date, histopathological diagnosis, population group, gender, age, anatomical 
site of the lesion, and health sector. The study was conducted in accordance with ethical principles 
contained in the Helsinki Declaration.[17] It was approved by the Faculty of Health Sciences Ethics 
Committee for the University of Cape Town. (HREC/REF: 357/2015) 
  
All histologically-confirmed new primary cutaneous malignancies in public and private sector paediatric 
and adult patients, from towns within the NC and between the study dates (above) were eligible to be 
included.  Exclusion criteria included new primary cutaneous malignancies that were not incident cases, 
cutaneous metastases, squamous cell carcinoma (SCC) of the tongue, palate, buccal mucosa, vagina and 
anus and KS of the tonsil, tongue, larynx and nasopharynx. 
 




Before analysisng the data, the Data Management and Statistical Analysis Unit (DMSA) of the 
University of the Witwatersrand used a hot-deck imputation method to correlate cases with no 
population group against a reference database containing surnames with a known population group. This 
enabled estimates of population group for each patient to be made, as was used by NCR in 1998 when 
they faced a similar dilemma. The method proved to be accurate and its results compared well with 
previous registry statistics.[18-20]  
 
For the primary analysis two software packages were used, namely, SPSS Statistics (Version 21, IBM 
Corporation) and R (Version 3.1.3, 64-bit version, R Foundation for Statistical Computing). The 
statistical analysis was divided into three components. The first component involved establishing the 
main types of skin cancer with respect to patient’s demographic and histological data. Empirical 
descriptive statistics were calculated. The Kruskal-Wallis test for similarities in age distribution between 
different types of cutaneous malignancies was performed as the data were not normally distributed. 
 
The second component involved calculating the incidence of the five most common cutaneous 
malignancies for each year. Throughout this work incidence refers to yearly cumulative incidence which 
is the proportion of those at risk who acquire cancer over a one year period. The incidence of each 
malignancy was calculated using the total number of new histologically-confirmed cases of a skin 
cancer type in a particular year as the numerator, with the NC mid-year population estimate for the year 
as the denominator. This was reported as incidence per 100 000/year.  
 
The third component investigated trends in incidence and melanoma thickness over the five years. 
Logistic regression modelling was used to estimate annual incidence trends controlling for potential 
confounders. The Hochberg procedure was used to adjust for multiple comparisons. The level of 
significance was set at a two-sided p-value (p < 0.05). To investigate trends in melanoma thickness over 
five years, the Clark’s staging data was collapsed into “High stage” and “Low stage” categories for 
analysis. “Low stage” included Clark’s levels 1 and 2, and “High stage” included Clark’s levels 3 to 5. 
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Results 
 
4270 biopsies comprising 14 cutaneous malignancies were identified. The five most common invasive 
malignancies made up 82.7 % of all the cases. In descending order they were: SCC, basal cell carcinoma 




Demographics of the five most common invasive skin cancers 
Population group distribution comprised 2093 (52%) White, 1047 (26%) Black, 864 (21.4%) Coloured 
and 23 (0.6%) Indian/Asian patients. Imputed population group was unspecified in 243 patients. BCC, 
CMM and BSC occurred relatively more frequently in White individuals than in other population 
groups. A high rate of SCC was observed within White, Black and Coloured individuals. KS occurred 
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Male/female ratio was 1:1 (2108 males, 2095 females). Gender was unspecified in 67 patients. All five 
of the most common invasive cutaneous malignancies affected males more frequently than females, with 
BSC occurring twice as often in males. Squamous cell carcinoma in situ (SCCI) represents the major 
exception to this trend, occurring six times more frequently in females. 
 
Age range spanned 2 -101 years with a mean age of 51.6 years. There was a statistically significant 
difference in age distribution between malignancies                   (p <0.001). BCC occurred most 
frequently in the age group 60-69 years, while CMM and SCC presented most commonly in those aged 
50-59 years and BSCs in those aged 70-79 years. The majority of KS occurred in the younger age group 
30-39 years.  
 
Head and neck regions were the most common anatomical sites affected by BCC, SCC and BSC. CMM 
occurred most commonly overall on the lower limb with the trunk and lower legs being most frequently 
affected in men and women, respectively. 
 
Of the 4270 biopsies, 2448 (57%) and 1822 (43%) were from the public and private healthcare sectors, 
respectively. In decreasing order of frequency BCC, SCC and CMM occurred most frequently within the 
private sector while SCC followed by KS accounted for the majority of the pathology within the public 
sector (Figure 2). Ninety percent (n=1061) of the BCCs occurred within private sector patients, while 
73% (n=1417) of SCCs identified were from the public sector. Of the 101 patients with CMM, 62% (n 
=63) were from the private sector while 38% (n=38) were from the public sector. 84% of the private 
sector patients were White, while within the public sector 27% were White, 43% were Black and 29% 
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1524 (79%) of patients with invasive SCC could be categorised according to tumour differentiation. Of 
these, 21% were well-differentiated, while 59% were moderately-differentiated and 20% were poorly-
differentiated. In both the Coloured and Black populations almost one quarter of malignancies were 
poorly differentiated.  
 
Incidence and five-year incidence trends 
Table 3 reports the incidence of the five most common invasive cutaneous malignancies per 100 000, 
from 2008 to 2012, as well as the estimated ORs of each cancer for a one-year increase. Incidence was 
then plotted and logistic regression was used to model trends. Categories in bold type in Table 3 are 
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The odds of a Black male developing KS or SCC decreased by 18% (OR: 0.82; CI: 0.70-0.97; p-value: 
0.0222) and 9% (OR: 0.91;CI: 0.84-0.99; p-value: 0.0336) respectively, every year over the five-year 
period. In contrast, the odds of a White male developing BSC or SCC increased by 45% (OR: 1.45; CI: 
1.08-1.99; p-value: 0.0177) and 8% (OR: 1.08; CI: 1.01-1.15; p-value: 0.0225) respectively.  Once the 
Hochberg procedure was applied, significant trends in incidence were not observed. 
 
Trends in melanoma thickness 
55% of CMMs were not sub-typed and 25% were still in the insitu phase at the time of excision. Acral 
lentiginous melanoma (ALM) was the sub-type that occurred most frequently and all cases of this sub-
type occurred within the public sector. Clark level for CMM within the private sector ranged from 1 - 4 
(mean: 2.7) while in the public sector it ranged from 2 - 5 (mean: 4.2). Only in 2012 were no cases with 
a Clark level 5 seen. Once Clark’s staging data were collapsed into low and high stages and a logistic 
regression model was applied, the OR for low stage depth for every one-year increase from 2009 to 
2012 was estimated to be 1.72 (95% CI: 1.04 -3.01; p-value: 0.0429). This indicates that the odds of a 
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Discussion 
 
SCC, BCC, KS and CMM were the four most frequently occurring skin cancers in the NC Province in 
accordance with the 2004 national statistics published by NCR.[21] SCC was the most frequent cutaneous 
malignancy seen between 2008 and 2012 and high rates were observed within White, Black and 
Coloured population groups. SCC incidence has risen worldwide over the past several decades at an 
estimated 3-10% per year.[22] The vast majority of NMSC is attributed to personal UVR exposure and 
SA is located within the Southern hemisphere, which has a greater intensity of UVR compared to a 
Northern hemisphere site at a similar latitude.[1, 23] Another contributor may be that 18.5 % of the 
currently employed NC population works within the agricultural industry,[3] which is more than double 
the proportion of the population working in agriculture in any other province. These individuals working 
outdoors have a 43% and 77% higher risk of BCC and SCC, respectively.[5, 6] In addition, HIV 
prevalence in the NC in 2011 was 17%,[24] and individuals with this disease have an increased risk of 
developing NMSC.[8] The HIV status of the patients included in this study was unknown but infection 
with this virus may have contributed to the high observed SCC incidence.  
 
SCC and BCC tend to occur more frequently in men,[25] and this study found this observation to be true 
(male to female ratio of 1.1:1 for SCC and 1.7:1 for BCC). Around 75% of SCCI occurs in women,[26] 
but an even higher rate (87%) was seen here.  
 
A sharp increase in BCC incidence was seen post 60 years, but in contrast to the literature,[25] the 
majority of SCC developed in a younger age group (i.e. 50-59 years). The same factors that may have 
contributed to the higher SCC incidence seen here may also have contributed to earlier presentation of 
SCC observed. KS observed was most likely of acquired immune deficiency syndrome (AIDS)-related 
type, hence KS was used as a proxy for HIV status. The South African National HIV Prevalence, 
Incidence and Behaviour survey in 2012 found that women aged 30-34 years and males aged 35-39 
years had the highest HIV infection rates,[27] thus it is not surprising that here the KS peak incidence 
occurred within the age group 30-39 years. 
 
 
The population group distribution within each health sector is likely to have influenced the range of 
malignancies seen within them. White individuals made up the majority of private sector patients and it 
can be assumed that these patients would have a skin type I, II or III on the Fitzpatrick phototype 
classification scale.[28] This may explain the predominant pathology seen within the private sector, which 
in decreasing order included BCC, SCC and CMM. Black patients made up nearly half of public sector 
patients. SCC and KS are reportedly the most common malignancies occurring within Black patients, 
which may explain why these pathologies accounted for majority of skin cancer within the public 
sector.[29, 30]  
 
Poorly-differentiated SCC occurred in a higher percentage of Black and Coloured individuals than 
White individuals. Poorly differentiated sub-types tend to occur in late presentations in which the 
tumour is already advanced, more likely to metastasise and has a poorer prognosis.[31] An explanation for 
the high frequency of this sub-type in dark skin individuals may be the lower perceived risk of skin 
cancer by these patients.    
 
Between 2008 and 2012, the odds of a Black male developing KS or SCC decreased significantly. A 
possible explanation for this decline may be that the roll-out of antiretroviral therapy (ART) in the NC 
only commenced in July 2004, at which time only 6.6% of HIV positive patients requiring ART were 
receiving them.[32] In contrast, by 2008, 90.4% of these individuals were receiving ARTs.[32] Most of the 
increase in CD4 count after starting ART occurs within the first three years.[33] As the incidence of both 
SCC and KS are influenced by HIV and immune status, improvement in many individuals immune 
status following ART initiation after 2004 may explain the declining rates of these pathologies a few 
years later.[8] The rising incidence of BCC and SCC amongst White males between 2008 and 2012 
concurs with a recent systematic review of the global incidence of NMSC, which found an increase in its 
incidence in White populations worldwide.[9]  
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No significant trend was seen in CMM incidence in all races and genders between 2008 and 2012. ALM 
was the sub-type most commonly observed and all cases occurred within the public sector and majority 
were of an advanced depth (mean Breslow depth: 4.13). A Breslow depth of greater than or equal to 4 
mm has a five-year survival of 37-50%.[15] ALMs are often diagnosed at an advanced stage due to 
difficulty in distinguishing them from ethnic pigmentation or traumatic skin changes. In addition, most 
practitioners have an increased threshold for performing biopsies in acral sites due to associated delayed 
healing times and morbidity. CMMs within the public sector were diagnosed at a more advanced stage. 
Socioeconomic factors influence disease outcomes in CMM and less affluent groups generally have 
more advanced disease and poorer survival rates.[34] In addition to the afore-mentioned factors, longer 
waiting times for appointments within the public sector may impact on late diagnosis. Tumour thickness 
is an indicator of the effectiveness of the early detection of melanomas,[16] and in many countries there is 
an ongoing trend toward early detection and therefore thinner melanomas being discovered as well as an 
increase in percentage of melanoma insitu diagnosed.[16] The fact that one quarter of melanomas were 
still in the insitu phase at the time of excision and that the odds of a low stage depth were found to 
increase from one year to the next,  confirmed that CMM within the NC is also being detected at an 
earlier stage. 
 
Study limitations included using only histologically-confirmed cases of skin malignancy. Some 
malignancies (i.e. BCCs or KS) may have been diagnosed based on characteristic clinical features and 
treated without histological confirmation resulting in underestimation of the true cumulative incidence.  
The sparsely populated NC is a large province[35] and is bordered by Namibia, Botswana and other 
provinces.[35] It is plausible that some individuals living within a particular region may have sought 
treatment for suspicious skin lesions in nearby cities, which fall under other provinces, and this may 
have led to skewing of the figures. HIV status of participants included in the study was unknown. As 
HIV increases risk for developing a NMSC,[8] this may have influenced the incidence of NMSC 
observed. Very little patient history was supplied on the majority of histopathology request forms and 
this was a limitation in regard to SCC, as one could not distinguish whether the malignancy arose within 
a scar, chronic ulcer or on sun exposed skin. There are no NC skin cancer statistics to refer or compare 




This is the first South African study to collate and analyse public and private sector skin cancer data for 
an entire province. These data impart insight into the skin cancer burden faced by the NC Province and 
provide a basis for future monitoring of skin cancer incidence. They also supply a framework to measure 
effectiveness of skin cancer prevention programmes within the province. Skin cancer patterns within 
South Africa are changing. There is a need for the equitable appropriation of greater financial resources 
and effort toward developing primary prevention initiatives tailored to a South African context in order 
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Appendix: 1 Clark level [16] 
It describes the level of anatomical invasion by a tumour. 
Level 1: All tumour cells are confined to the epidermis, above the basement membrane (insitu) 
Level 2: Tumour invades into the papillary dermis, beyond the basement membrane 
Level 3: Tumour fills the papillary dermis and extends into the interface between the papillary and 
              reticular dermis 
Level 4: Tumour invades the reticular dermis 
Level 5: Tumour has invades the subcutaneous fat 
 
Appendix 2: Breslow depth [16] 
Breslow’s depth of invasion is a measurement of the depth of invasion of the lesion. It is measured 
vertically in millimetres from the top of the granular layer of the epidermis to the deepest point of 
tumour involvement. The Breslow thickness is used in the TNM staging system of a melanoma. 
Tumours are classified into to four categories based on the depth: 
• Less than 1mm thick (95-100% five-year survival) 
• Between 1mm-2mm thick (80-96% five-year survival) 
• Between 2mm-4mm thick (60-75% five-year survival) 









	   41	  
Appendix 3: Faculty of Health Sciences Ethics Committee for the University of Cape Town 






	   42	  






	   43	  







	   44	  






	   45	  






Accepted manuscripts that are not in the correct format specified in these guidelines will be 
returned to the author(s) for correction, and will delay publication. 
 
AUTHORSHIP 
Named authors must consent to publication. Authorship should be based on: (i) substantial contribution 
to conception, design, analysis and interpretation of data; (ii) drafting or critical revision for important 
intellectual content; or (iii) approval of the version to be published. These conditions must all be met 
(uniform requirements for manuscripts submitted to biomedical journals; refer to www.icmje.org). 
 
CONFLICT OF INTEREST 
Authors must declare all sources of support for the research and any association with a product or 
subject that may constitute conflict of interest. 
 
RESEARCH ETHICS COMMITTEE APPROVAL 
Provide evidence of Research Ethics Committee approval of the research where relevant. 
 
PROTECTION OF PATIENT'S RIGHTS TO PRIVACY 
Identifying information should not be published in written descriptions, photographs, and pedigrees 
unless the information is essential for scientific purposes and the patient (or parent or guardian) gives 
informed written consent for publication. The patient should be shown the manuscript to be published. 
Refer to www.icmje.org. 
 
ETHNIC CLASSIFICATION 
References to ethnic classification must indicate the rationale for this. 
 
MANUSCRIPTS 
Shorter items are more likely to be accepted for publication, owing to space constraints and reader 
preferences. 
Research articles (previously 'Original articles') not exceeding 3 000 words, with up to 6 tables or 
illustrations, are usually observations or research of relevance to clinical medicine and related fields. 
Please provide a structured abstract not exceeding 250 words, with the following recommended 
headings: Background, Objectives, Methods, Results, and Conclusion. 
Scientific letters will be considered for publication as shorter Research articles.  
Editorials, Opinions, etc. should be about 1000 words and are welcome, but unless invited, will be 
subjected to the SAMJ peer review process. 
Review articles are rarely accepted unless invited. 
Letters to the editor, for publication, should be about 400 words with only one illustration or table, and 
must include a correspondence address. 
Forum articles must be accompanied by a short description (50 words) of the affiliation details/interests 
of the author(s). Refer to recent forum articles for guidance. Please provide an accompanying abstract 
not exceeding 150 words. 
Book reviews should be about 400 words and must be accompanied by the publication details of the 
	   46	  
book. 
Obituaries should be about 400 words and may be accompanied by a photograph. 
Guidelines must be endorsed by an appropriate body prior to consideration and all conflicts of interest 
expressed. A structured abstract not exceeding 250 words (recommended sub-headings: Background, 
Recommendations, Conclusion) is required. Sections and sub-sections must be numbered consecutively 
(e.g. 1. Introduction; 1.1 Definitions; 2. etc.) and summarised in a Table of Contents. References, 
appendices, figures and tables must be kept to a minumum. 
Guidelines exceeding 8 000 words will only be considered for publication as a supplement to the 
SAMJ; the costs of which must be covered by sponsorship or advertising. The Editor reserves the right 
to determine the scheduling of supplements. Understandably, a delay in publication must be 
anticipated dependent upon editorial workflow. 
  
MANUSCRIPT PREPARATION 
Refer to articles in recent issues for the presentation of headings and subheadings. If in doubt, refer to 
'uniform requirements' - www.icmje.org. Manuscripts must be provided in UK English. 
Qualification, affiliation and contact details of ALL authors must be provided in the manuscript and 
in the online submission process. 
Abbreviations should be spelt out when first used and thereafter used consistently, e.g. 'intravenous 
(IV)' or 'Department of Health (DoH)'. 
Scientific measurements must be expressed in SI units except: blood pressure (mmHg) and 
haemoglobin (g/dl). Litres is denoted with a lowercase 'l' e.g. 'ml' for millilitres). Units should be 
preceded by a space (except for %), e.g. '40 kg' and '20 cm' but '50%'. Greater/smaller than signs (> 
and 40 years of age'. The same applies to ± and º, i.e. '35±6' and '19ºC'. 
Numbers should be written as grouped per thousand-units, i.e. 4 000, 22 160... 
Quotes should be placed in single quotation marks: i.e. The respondent stated: '...' Round brackets 
(parentheses) should be used, as opposed to square brackets, which are reserved for denoting 
concentrations or insertions in direct quotes. 
General formatting The manuscript must be in Microsoft Word or RTF document format. Text must 
be single-spaced, in 12-point Times New Roman font, and contain no unnecessary formatting (such as 
text in boxes, with the exception of Tables). 
 
ILLUSTRATIONS AND TABLES 
If tables or illustrations submitted have been published elsewhere, the author(s) should provide consent 
to republication obtained from the copyright holder. 
Tables may be embedded in the manuscript file or provided as 'supplementary files'. They must be 
numbered in Arabic numerals (1,2,3...) and referred to consecutively in the text (e.g. 'Table 1'). Tables 
should be constructed carefully and simply for intelligible data representation. Unnecessarily 
complicated tables are strongly discouraged. Tables must be  accompanied by a concise title and 
column headings. Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § 
¶ || then ** †† ‡‡ etc. 
Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. Figure legends: 
Fig. 1. 'Title...' All illustrations/figures/graphs must be of high resolution/quality: 300 dpi or more is 
preferable, but images must not be resized to increase resolution. TIFF and PNG formats are 
preferable; JPEG and PDF formats are accepted, but authors must be wary of image compression. 




Authors must verify references from original sources. Only complete, correctly formatted reference lists 
will be accepted. Reference lists must be generated manually and not with the use of reference 
manager software. Citations should be inserted in the text as superscript numbers between square 
	   47	  
brackets, e.g. These regulations are endorsed by the World Health Organization,[2] and others.[3,4-6] All 
references should be listed at the end of the article in numerical order of appearance in the Vancouver 
style (not alphabetical order). Approved abbreviations of journal titles must be used; see the List of 
Journals in Index Medicus. Names and initials of all authors should be given; if there are more than six 
authors, the first three names should be given followed by et al. First and last page, volume and issue 
numbers should be given. 
Wherever possible, references must be accompanied by a digital object identifier (DOI) link and 
PubMed ID (PMID)/PubMed Central ID (PMCID). Authors are encouraged to use the DOI lookup 
service offered by CrossRef. 
Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about glaucoma. 
Stat Med 1998;289(1):350-355. [http://dx.doi.org/10.1000/hgjr.182] [PMID: 2764753] 
Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 1975:96-101. 
Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of Invading 
Microorganisms. In: Sodeman WA jun, Sodeman WA, eds. Pathologic Physiology: Mechanisms of 
Disease. Philadelphia: WB Saunders, 1974:457-472. 
Internet references: World Health Organization. The World Health Report 2002 - Reducing Risks, 
Promoting Healthy Life. Geneva: World Health Organization, 2002. http://www.who.int/whr/2002 
(accessed 16 January 2010). 
Other references (e.g. reports) should follow the same format: Author(s). Title. Publisher place: 
publisher name, year; pages. Cited manuscripts that have been accepted but not yet published can be 
included as references followed by '(in press)'. Unpublished observations and personal 
communications in the text must not appear in the reference list. The full name of the source person 
must be provided for personal communications e.g. '...(Prof. Michael Jones, personal communication)'. 
 
PROOFS 
A PDF proof of an article may be sent to the corresponding author before publication to resolve 
remaining queries. At that stage, only typographical changes are permitted; the corresponding author is 
required, having conferred with his/her co-authors, to reply within 2 working days in order for the article 
to be published in the issue for which it has been scheduled. 
 
CHANGES OF ADDRESS 




Authors can earn up to 15 CPD CEUs for published articles. Certificates may be requested after 
publication of the article. 
 
CHARGES 
There is no charge for the publication of manuscripts. 




Submission Preparation Checklist 
As part of the submission process, authors are required to check off their submission's compliance with 
all of the following items, and submissions may be returned to authors that do not adhere to these 
guidelines. 
• Named authors consent to publication and meet the requirements of authorship as set out by the 
journal. 
• The submission has not been previously published, nor is it before another journal for consideration. 
• The text complies with the stylistic and bibliographic requirements in Author Guidelines. 
	   48	  
• The manuscript is in Microsoft Word or RTF document format. The text is single-spaced, in 12-point 
Times New Roman font, and contains no unnecessary formatting. 
• Illustrations/figures are high resolution/quality (not compressed) and in an acceptable format 
(preferably TIFF or PNG).  
• For illustrations/figures or tables that have been published elsewhere, the author has obtained written 
consent to republication from the copyright holder. 
• Where possible, references are accompanied by a digital object identifier (DOI) and PubMed ID 
(PMID)/PubMed Central ID (PMCID). 
• An abstract has been included where applicable. 
• The research was approved by a Research Ethics Committee (if applicable) 
• Any conflict of interest (or competing interests) is indicated by the author(s). 
  
 
	  
